Clinical trials: COVID19 ARDS
Covid19, COVID-19 Pneumonia
Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)
COVID-19 is respiratory disease caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2), a novel coronavirus which has spread rapidly across the world with over 149.9 million laboratory confirmed cases and over 3.1…
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Lower Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- COVASP (NCT04896866)
- Testing
- Antimicrobial stewardship prospective audit and feedback
- Where
- 3 sites in Canada
- Volunteers
- 833 people
- Sponsor
- University of Alberta
Covid19, ARDS, Human
Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients
The purpose of this study is to monitor short-term changes in tissue oxygen saturation and local blood flow as results of changing from supine to prone position in ARDS COVID-19 patients
- Trial name
- PRONECOVID19 (NCT04692129)
- Where
- 6 sites in Brazil, Mexico and 1 more
- Volunteers
- 100 people
- Sponsor
- Corporacion Parc Tauli
Covid19, Respiratory Failure
Nebulised Heparin in Patients With Severe COVID-19
The Can nebulised HepArin Reduce morTality and time to Extubation in Patients with COVID-19 Requiring mechanical ventilation Meta-Trial (CHARTER-MT) is a prospective collaborative individual patient data analysis of randomised…
- Trial name
- CHARTER-MT (NCT04545541)
- Testing
- Nebulised unfractionated heparin (UFH)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Australian National University
Covid19, Acute Respiratory Failure
Survival Rates and Longterm Outcomes After COVID-19
The study 'Survival rates and long-term outcomes for patients with COVID-19 admitted to Norwegian ICUs' is a national observational study, including patients admitted to a Norwegian ICU between March 2020 and March 2021.
- Conditions
- Covid19, Acute Respiratory Failure, Acute Respiratory Distress Syndrome, Post Intensive Care Unit Syndrome
- Trial name
- NCT04601090
- Testing
- ICU treatment
- Where
- Norway
- Volunteers
- 860 people
- Sponsor
- Oslo University Hospital
COVID, ARDS
Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19
This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less…
- Trial name
- NCT04614025
- Testing
- PLX-PAD
- Where
- 9 sites in Germany, Israel
- Volunteers
- 23 people
- Sponsor
- Pluristem Ltd.
COVID-19
ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19
This study is open to adults with COVID-19 infection who are in hospital and receive oxygen. Participants need to be 50 years of age or older and need to be at risk of further worsening of their condition.
- Trial name
- NCT04604184
- Testing
- BI 764198
- Where
- 25 sites in United States, Brazil and 4 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04312009
- Testing
- Losartan
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- University of Minnesota
ARDS, COVID-19
Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)
To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS…
- Trial name
- NCT04377334
- Testing
- MSC
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Tuebingen
COVID-19, ARDS, Human
Cardiac Dysfunction in Critically Ill Covid-19 Patients
We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", in which we analysed the echocardiographic data collected both at…
- Conditions
- COVID-19, ARDS, Human, Cardiac Failure, Right Ventricular Dysfunction
- Trial name
- NCT06197256
- Where
- Sweden
- Volunteers
- 39 people
- Sponsor
- Region Stockholm
COVID, Severe Acute Respiratory Syndrome
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
To evaluate the proportion of subjects alive and free of respiratory failure (e.g. need for non-invasive or invasive mechanical ventilation, high flow oxygen, or ECMO) and free of the need for continued renal replacement therapy…
- Conditions
- COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury
- Trial name
- NCT04402957
- Testing
- LSALT peptide
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 61 people
- Sponsor
- Arch Biopartners Inc.
Critically Illness, Sedation
Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intravenous sedation.
- Conditions
- Critically Illness, Sedation, Invasive Mechanical Ventilation, Acute Respiratory Distress Syndrome
- Trial name
- ISCA (NCT04383730)
- Testing
- Intravenous sedation, Inhaled sedation
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 203 people
- Sponsor
- University Hospital, Clermont-Ferrand
Respiratory Distress Syndrome, Adult
A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.
- Trial name
- NCT04582201
- Testing
- agenT-797
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- MiNK Therapeutics
Corona Virus Infection, Acute Respiratory Distress Syndrome
Losartan for Patients With COVID-19 Not Requiring Hospitalization
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Trial name
- NCT04311177
- Testing
- Losartan
- Where
- 4 sites in United States
- Volunteers
- 117 people
- Sponsor
- University of Minnesota
Corona Virus Infection, COVID-19
Zofin (Organicell Flow) for Patients With COVID-19
The purpose of this research study is to evaluate the safety and potential efficacy of Intravenous Infusion of Zofin for treatment of moderate to severe Acute Respiratory Syndrome (SARS) related to COVID-19 infection vs Placebo.
- Conditions
- Corona Virus Infection, COVID-19, SARS, Acute Respiratory Distress Syndrome
- Trial name
- NCT04384445
- Testing
- Zofin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ZEO ScientifiX, Inc.
COVID, ARDS
Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19
This clinical trial will examine if a new treatment of Mesenchymal-like Adherent stromal Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less…
- Trial name
- NCT04389450
- Testing
- PLX-PAD
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Pluristem Ltd.
ARDS Secondary to COVID-19 Pneumonia
CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome
Respiratory involvement of SARS-CoV2 leads to acute respiratory distress syndrome (ARDS) and significant immunosuppression (lymphopenia) exposing patients to long ventilation duration and late mortality linked to the acquisition…
- Trial name
- CACOLAC (NCT04404426)
- Testing
- L-citrulline
- Where
- France
- Volunteers
- 33 people
- Sponsor
- Rennes University Hospital
COVID-19
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
- Trial name
- NCT04422678
- Testing
- Imatinib Mesylate, Standard of Care
- Volunteers
- 30 people
- Sponsor
- Alexandria University
Conscious Sedation, Pathologic Processes
Prospective Electroencephalography Evaluation of Sedation in COVID-19
Sedation of severe COVID-19 disease are often complicated. We try to find a correlate for this observation by encephalographic studies.
- Conditions
- Conscious Sedation, Pathologic Processes, Electroencephalogram, Acute Respiratory Distress Syndrome
- Trial name
- NCT04815109
- Testing
- Encephalography measurement
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Goethe University
ARDS, Human, COVID-19
London's Exogenous Surfactant Study for COVID19
The research team is investigating administering exogenous surfactant in COVID-19 patients with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated COVID-19 patients.
- Trial name
- LESSCOVID (NCT04375735)
- Testing
- Bovine Lipid Extract Surfactant
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's